acquisitions Archives - Vista Partners LLC

Is NAYA Therapeutics the Next Radiopharma Takeout? The Pipeline, the Board, and the Buzz – ( $AZN $BMY $IBB $LLY $NVS $XBI )

by John F. Heerdink, Jr. 19 hours ago 65Views 0Likes

NAYA Therapeutics (https://www.nayatx.com) is quietly trying to make “next‑gen radiopharma” sound less like sci‑fi and more like standard operating procedure—and its new board lineup reads like a who’s who of oncology, nuclear medicine, and biotech capital markets. A New Board for a…

Servier’s $2.5 Billion Bet on Rare Oncology: A Strategic Day One Biopharmaceuticals Play With a Pediatric Pulse -( $DAWN $XBI $IBB )

by John F. Heerdink, Jr. March 6, 2026 827Views 0Likes

French pharmaceutical group Servier has quietly become one of the most methodical players in oncology—and its latest move underscores that reputation. The company announced a definitive agreement to acquire Day One Biopharmaceuticals (Nasdaq: DAWN) for $21.50 per share in cash, valuing the…

Eli Lilly’s Weight-Loss Empire Just Got Heavier with $2.4B Acquisition – And So Did Its Market Cap -( $LLY $NVO $SPY )

by John F. Heerdink, Jr. February 9, 2026 274Views 0Likes

Eli Lilly (LLY) has once again muscled its way to the top of the healthcare league tables, with its stock climbing as investors double down on the idea that obesity drugs are less a fad and more a new asset class. The…

IonQ’s $1.8 Billion SkyWater Deal: Building America’s First Vertically Integrated Quantum Chip Powerhouse

by John F. Heerdink, Jr. February 2, 2026 335Views 0Likes

IonQ’s (IONQ) decision to buy SkyWater Technology for $1.8 billion reads like a quantum-age industrial policy love story: a fast‑growing quantum upstart marries a scrappy U.S. chip foundry, and the honeymoon is scheduled right onshore. For investors, the deal is a bet…

Inside Biopharma’s 2025 Deal Wave: Record Licensing, Big Pharma M&A and a Frozen IPO Market -( $JPM $IBB $XBI $LLY $MRK $NVS $PFE )

by John F. Heerdink, Jr. January 21, 2026 214Views 0Likes

Biopharma spent 2025 behaving like a sector that has finally read the fine print on the cost of capital—and decided to let someone else pick up the bar tab. Licensing and M&A stepped into the role IPOs used to play, and did…

From Chatbots to “Do‑It‑For‑You” AI: Why Meta’s Manus $2B Deal Could Rewrite the Playbook -( $META )

by Vista Partners LLC December 31, 2025 247Views 0Likes

Meta’s agreed purchase of AI agent startup Manus for more than $2 billion reads like a late‑cycle plot twist: the social media giant that rebranded around the metaverse is now buying an AI “do‑it‑for‑you” brain to justify all that spending. In Wall…

Tag: acquisitions

Is NAYA Therapeutics the Next Radiopharma Takeout? The Pipeline, the Board, and the Buzz – ( $AZN $BMY $IBB $LLY $NVS $XBI )

Servier’s $2.5 Billion Bet on Rare Oncology: A Strategic Day One Biopharmaceuticals Play With a Pediatric Pulse -( $DAWN $XBI $IBB )

Eli Lilly’s Weight-Loss Empire Just Got Heavier with $2.4B Acquisition – And So Did Its Market Cap -( $LLY $NVO $SPY )

IonQ’s $1.8 Billion SkyWater Deal: Building America’s First Vertically Integrated Quantum Chip Powerhouse

Inside Biopharma’s 2025 Deal Wave: Record Licensing, Big Pharma M&A and a Frozen IPO Market -( $JPM $IBB $XBI $LLY $MRK $NVS $PFE )

From Chatbots to “Do‑It‑For‑You” AI: Why Meta’s Manus $2B Deal Could Rewrite the Playbook -( $META )

Your Guide To Staying Informed In The Markets